PUVA versus NB-UVB in Management of Vitiligo, Clinico-Immuno-Pathological Study
24
NB-UVB repigmentation more than in the PUVA treated
areas. Thus, PUVA may provide better immuno-modu-
latory effect on vitiligo than NB-UVB and may give bet-
ter response regarding the disease reactivation and recur-
rence. A combination of UVA and NB-UVB bulbs in
same treating cabinets maybe recommended obtaining
better treatment results.
REFERENCES
[1] S. O. Kovacs, “Vitiligo,” Journal of the American Acad-
emy of Dermatology, Vol. 38, No. 5, 1998, pp. 647-666.
[2] M. D. Njoo, W. Westerhof, J. D. Bos and P. M. Bossuyt,
“The Development of Guidelines for the Treatment of
Vitiligo,” Archiv es of Dermatology, Vol. 135, No. 12, 1999,
pp. 1514-1521.
http://dx.doi.org/10.1001/archderm.135.12.1514
[3] T. M. Runger, “Ultraviolet Light,” In: J. L. Bolognia, J. L.
Jorizzo, R. P. Rapini, T. D. Horn, A. J. Maoncini, J. M.
Mascaro, S. J. Salasche, J. H. Saurat and G. Stingl, Eds.,
Dermatology, Mosby, Edinburgh, London, New York,
Oxford, Philadelphia, St. Louis, Sydney, Toronto, Vol. 1,
2003, pp. 1353-1364.
[4] M. El-Mofty and H. El-Sawaalhy, “Clinical Study of a
New Preparation of 8-Methoxypsoralen in Photochemo-
therapy,” International Journal of Dermatology, Vol. 33,
No. 8, 1994, pp. 688-703.
http://dx.doi.org/10.1111/j.1365-4362.1994.tb02904.x
[5] D. Parsad, A. J. Kanwar and B. Kumar, “Psoralen-Ultra-
violet A vs. Narrowband Ultraviolet B Phototherapy for
the Treatment of Vitiligo,” Journal of the European Aca-
demy of Dermatology and Venereology, Vol. 20, No. 2,
2006, pp. 175-177.
http://dx.doi.org/10.1111/j.1468-3083.2006.01413.x
[6] A. K .Gupta and T. F. Anderson, “Psoralen Photochemo-
therapy,” Journal of the American Academy of Derma-
tology, Vol. 17, No. 5, 1987, pp. 703-734.
http://dx.doi.org/10.1016/S0190-9622(87)70255-2
[7] S. S. Yones, D. Der, A. Roy, et al., “Efficacy of Psora le n-
UV-A Therapy vs Narrowband-UV-B Therapy,” Archives
of Dermatology, Vol. 143, No. 5, 2007, pp. 578-584.
http://dx.doi.org/10.1001/archderm.143.5.578
[8] R. S. Dawe, J. Ferguson and S. H. Ibbotson, “A Study of
the Characteristics of Erythema Induced by Bath and Oral
Methoxsalen Photochemotherapy and Narrowband Ultra-
violet,” Journal of Photochemistry and Photobiology, Vol.
78, No. 1, 2003, pp. 55-60.
http://dx.doi.org/10.1562/0031-8655(2003)078<0055:AIS
OTC>2.0.CO;2
[9] Y. Kawakami, K. Jane, K. Takeshi, et al., “Production of
Recombinant MART -1 Protie ns and Specific AntiMART -
1 Polyclonal and Monoclonal Antibodies: Use in the Cha-
racterization of the Human Melanoma Antigen MART-
1,” Journal of Immunological Methods, Vol. 202, No. 1,
1997, pp. 13-25.
http://dx.doi.org/10.1016/S0022-1759(96)00211-6
[10] S. S. Awad, H. Abdel-Raof, W. Hosam El-Din and M.
El-Domyati, “Epithelial Grafting for Vitiligo Requires
Ultraviolet A Phototherapy to Increase Success Rate,”
Journal of Cosmetic Dermatology, Vol. 6, No. 2, 2007,
pp. 119-124.
http://dx.doi.org/10.1111/j.1473-2165.2007.00307.x
[11] M. D. Njoo, J. D. Bos and W. Westerhof, “Treatment of
Generalized Vitiligo in Children with Narrow-Band (TL-
01) UVB Radiation Therapy,” Journal of the American
Academy of Dermatology, Vol. 42, No. 2, 2000, pp. 245-
253. http://dx.doi.org/10.1016/S0190-9622(00)90133-6
[12] M. El Mofty, W. Mostafa, S. Esmat, et al., “Narrow Band
Ultraviolet B 311 nm in the Treatment of Vitiligo: Two
Right-Left Comparison Studie s,” Photodermato logy, Photo-
immunology & Photomedicine, Vol. 22, No. 1, 2006, pp.
6-11. http://dx.doi.org/10.1111/j.1600-0781.2006.00189.x
[13] W. Westerhof and L. Nieuweboer-Krobotova, “Treatment
of Vitiligo with UV-B Radiation vs Topical Psoralen Plus
UV-A,” Archives of Dermatology, Vol. 133, No. 12, 1997,
pp. 1525-1528.
http://dx.doi.org/10.1001/archderm.1997.03890480045006
[14] I. Hamzavi, H. Jain, D. McLean, et al., “Parametric Mod-
eling of Narrowband UV-B Phototherapy for Vitiligo
Using a Novel Quantitative Tool,” Archives of Derma-
tology, Vol. 140, No. 6, 2004, pp. 677-683.
http://dx.doi.org/10.1001/archderm.140.6.677
[15] A. Simin, S. Sedef, B. Gonca and K. Fikret, “No Addi-
tional Effect of Topical Calcipotriol on Narrow Band
UVB Phototherapy in Patients with Generalized Vitiligo,”
Photodermatology, Photoimmunology & Photomedicine,
Vol. 21, No. 2, 2005, pp. 79-83.
http://dx.doi.org/10.1111/j.1600-0781.2005.00139.x
[16] S. M. Halpern, A. Anstey and R. S. Dawe, “Guidelines
for Topical PUVA: A Report of a Workshop of the Brit-
ish Photodermatology Group,” British Journal of Der-
matology, Vol. 142, No. 1, 2000, pp. 22-31.
http://dx.doi.org/10.1046/j.1365-2133.2000.03237.x
[17] S. Valkova, M. Trashlieva and P. Christova, “Treatment
of Vitiligo with Local Khellin and UVA: Comparison
with Systemic PUVA,” Clinical and Experimental Der-
matology, Vol. 29, No. 2, 2004, pp. 180-184.
http://dx.doi.org/10.1111/j.1365-2230.2004.01462.x
[18] S. Sahin, U. Hindioglu and A. Karaduman, “PUVA
Treatment of Vitiligo: A Retrospective Study of Turikish
Patients,” International Journal of Dermatology, Vol. 38,
No. 7, 1999, pp. 542-545.
http://dx.doi.org/10.1046/j.1365-4362.1999.00654.x
[19] T. S. Anbar, W. Westerhof, A. T. Abdel-Rahman and M.
A. El-Khayyat, “Evaluation of the Effects of NB-UVB in
Both Segmental and Non-Segmental Vitiligo Affecting
Different Body Sites,” Photodermatology, Photoimmu-
nology & Photomedicine, Vol. 22, No. 3, 2006, pp. 157-
163. http://dx.doi.org/10.1111/j.1600-0781.2006.00222.x
[20] R. S. Stern, “The Risk of Melanoma in Association with
Long-Term Exposure to PUVA,” Journal of the Ameri-
can Academy of Dermatology, Vol. 44, No. 5, 2001, pp.
755-761. http://dx.doi.org/10.1067/mjd.2001.114576
[21] Y. C. Kim, H. Y. Kang, S. Seonghyang and E. S. Lee,
“Histopathologic Features in Vitiligo,” The American
Journal of Dermatopathology, Vol. 30, No. 2, 2008, pp.
112-115.
Open Access JCDSA